Status:
TERMINATED
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer
Eligibility Criteria
Inclusion
- Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer
- HbA1c \<5.7%
Exclusion
- Previous treatment for advanced disease
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT00372996
Start Date
February 1 2007
End Date
June 1 2014
Last Update
October 28 2015
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD Medical Center - La Jolla
La Jolla, California, United States, 92037
2
UCSD Moores Cancer Center
La Jolla, California, United States, 92093
3
UCSD Medical Center - Hillcrest
San Diego, California, United States, 92103
4
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
Washington D.C., District of Columbia, United States, 20010-3017